Araclon Biotech company has developed an experimental vaccine to improve early-stage Alzheimer’s symptoms; how effective can Alzheimer’s vaccine be?
The company developing the new Alzheimer’s vaccine has announced that the vaccine’s effectiveness is still under trial. According to an initial study conducted by the manufacturer company on a group of people with early Alzheimer’s symptoms, the vaccine has successfully managed to improve cognitive test results by more than 38 points compared to previous results.
The accumulation of a protein called “beta-amyloid” around nerve cells is the leading cause of nerve cell death and the onset of Alzheimer’s symptoms. This is why Alzheimer’s disease usually affects the elderly, as these molecules accumulate over time and cause nerve cell death. Research centers have developed a vaccine that specifically targets Amyloid-beta molecules to prevent this abnormal accumulation of molecules. There are different types of beta-amyloid proteins, including the most common type, Amyloid-beta 40, and the most toxic and damaging type, Amyloid-beta 42. However, due to the diversity of these proteins, it is challenging to target them, which reduces the vaccine’s efficacy effectively.
Although there is still uncertainty regarding the effectiveness of the Alzheimer’s vaccine due to the lack of studies conducted on it, it brings hope for improving the symptoms of this severe disease, as well as the quality of life and cognitive abilities of patients. Companies are working on developing more effective vaccines to combat this disease. Many medical studies are focused on treating Alzheimer’s and improving its symptoms, as it remains one of the most important healthcare topics. Recently, a new treatment method called transcranial pulsed stimulation has been used to manage and improve Alzheimer’s symptoms in older people, showing promising results.